(2020). Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: The PROLUNG Phase 2 randomized clinical trial.
Chicago Style (17th ed.) CitationEfficacy and Safety of Pembrolizumab Plus Docetaxel Vs Docetaxel Alone in Patients with Previously Treated Advanced Non-small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. 2020.
MLA (8th ed.) CitationEfficacy and Safety of Pembrolizumab Plus Docetaxel Vs Docetaxel Alone in Patients with Previously Treated Advanced Non-small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. 2020.
Warning: These citations may not always be 100% accurate.